1

How MedX technology can have your potential skin cancer diagnosed in 72 hours

“MedX is a company that has a visual technology that allows image capture not only on top of the skin but also below the skin. It allows us to take a look at a suspicious mole or lesion and be able to get that diagnosed by a dermatologist within 72 hours. That is the most important part, it is a triage unit, so we can get it to people who have melanoma and deal with it right away.” States Mike Druhan, Vice President of Corporate Development at MedX Health Corp. (TSXV: MDX), in an interview with InvestorIntel’s Tracy Weslosky.

Mike went on to say that MedX’s skin cancer diagnosis technology is a class 2 device which looks under the skin and can help a dermatologist can make an accurate assessment. He said that it is the only device in the world that does it. Mike also provided an update on the distribution agreement signed with Group Vida to distribute MedX’s DermSecure skin cancer assessment technology platform in the USA, Canada and Israel. He said that Group Vida has opened some very big channels for MedX already.

To access the complete interview, click here

Disclaimer: MedX Health Corp. is an advertorial member of InvestorIntel Corp.




Mike Druhan on the competitive advantages of MedX’s skin cancer diagnosis technology

“We have launched a new product called DermSecureTM…We can take a picture on the top of the skin of a melanoma or a potential melanoma or any type of skin cancer. We can look two millimeters below the skin. It is best image capture system in the world. We have coupled that on the top of a platform that allows us to be infinitely scalable on a global basis. That’s why you are starting to see the deals we are doing because of the acceptance and adoption of this technology.” States Mike Druhan, Vice President of Corporate Development at MedX Health Corp. (TSXV: MDX), in an interview with InvestorIntel’s Tracy Weslosky.

Tracy Weslosky: MedX Health is  one of the most exciting companies currently on the stock market in Canada. Can you tell the InvestorIntel audience why you are so competitive?

Mike Druhan: We are pretty excited right now. We have launched a new product called DermSecureTM and this is a platform that allows us to take our technology, which is our image capture technology, which is only one like it in the globe. We can take a picture on the top of the skin of a melanoma or a potential melanoma or any type of skin cancer. We can look two millimeters below the skin. It is best image capture system in the world. We have coupled that on the top of a platform that allows us to be infinitely scalable on a global basis. That’s why you are starting to see the deals we are doing because of the acceptance and adoption of this technology. It is very exciting time for MedX.

Tracy Weslosky: The keyword I heard here is, you are now scalable. Is that correct?

Mike Druhan: You have got it.

Tracy Weslosky: So, we are scalable and that means revenue. Does it not Mike?

Mike Druhan: Yes. Revenue is the big function. We have converted the technology with the platform to a SAAS model. So that means there is a lot of recurring revenue in our upcoming future and because we can quickly adapt large scale projects…to access the complete interview, click here

Disclaimer: MedX Health Corp. is an advertorial member of InvestorIntel Corp.